Interim miss slows IO Biotech
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
It’s back to school for biotech, with a packed conference schedule.
Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.